Tagrisso Shows Superiority vs. Chemo in EGFR T790M Mutation-Positive Disease

EGFR mutation linked to dramatically increased lung cancer risk

A rare inherited mutation in the Epidermal Growth Factor Receptor gene is associated with a 25-fold increased risk of lung cancer, according to a study by investigators at Dana-Farber Cancer Institute and 23andMe Research Institute.

September 18, 2026

Vol.52 No.34

Clinical Roundup

Ris-Rez reduced risk of death by 54% vs. topotecan in patients with relapsed SCLC, phase III trial in China finds

Hansoh Pharmaceutical Group announced positive overall survival data from ARTEMIS-008, its pivotal phase III trial in China, evaluating the B7-H3-targeted antibody-drug conjugate risvutatug rezetecan (Ris-Rez) versus topotecan in patients with relapsed small cell lung cancer whose disease progressed following platinum-based first-line therapy.

September 18, 2026

Vol.52 No.34

Clinical Roundup

Rybrevant + chemo delivers longest reported median OS in EGFR exon 20 insertion mutation-positive lung cancer

Patients with with advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations treated with intravenous Rybrevant (amivantamab-vmjw) plus carboplatin-pemetrexed chemotherapy achieved a median OS of nearly three years (34.3 months), compared with 27.9 months for chemotherapy alone, according to the final overall survival analysis of the phase III PAPILLON study.

September 18, 2026

Vol.52 No.34

Clinical Roundup

AI imaging endpoint predicts OS benefit in phase III lung cancer trial: data presented at IASLC WCLC 2026

Altis Labs Inc., the AI endpoint company accelerating clinical trials, on Sept. 17 announced findings from an independent post-hoc analysis evaluating its AI-powered imaging endpoint, IPRO, in the MARIPOSA phase III trial.

September 18, 2026

Vol.52 No.34

Podcast

9/11, mRNA, musical chairs—and an assassination attempt

This week’s oncology headlines run the gamut—from a discussion on the long-term consequences of 9/11 on lung cancer incidence, to the promise—and limits—of cutting edge mRNA science, to major institutional leadership changes, and even the intersection of cancer and war.

September 16, 2026

Cancer History Project

25 years after 9/11, a smoking cessation program may have curbed lung cancer risk for first responders at Ground Zero
“We seem to have a risk of exposure that needed that extra boost of the cigarette to cause the cancer.”

Twenty-five years ago, the attack on the World Trade Center engulfed Ground Zero in a shroud of smoke, leaving Lower Manhattan covered in toxic dust for months.

September 11, 2026

Vol.52 No.33

By Sara Willa Ernst

Tagrisso Shows Superiority vs. Chemo in EGFR T790M Mutation-Positive Disease

YOU MAY BE INTERESTED IN

EGFR mutation linked to dramatically increased lung cancer risk

Ris-Rez reduced risk of death by 54% vs. topotecan in patients with relapsed SCLC, phase III trial in China finds

Rybrevant + chemo delivers longest reported median OS in EGFR exon 20 insertion mutation-positive lung cancer

AI imaging endpoint predicts OS benefit in phase III lung cancer trial: data presented at IASLC WCLC 2026

9/11, mRNA, musical chairs—and an assassination attempt

25 years after 9/11, a smoking cessation program may have curbed lung cancer risk for first responders at Ground Zero
“We seem to have a risk of exposure that needed that extra boost of the cigarette to cause the cancer.”

Renew today!

Subscriber content

Never miss an issue!

Login

Tagrisso Shows Superiority vs. Chemo in EGFR T790M Mutation-Positive Disease

YOU MAY BE INTERESTED IN

EGFR mutation linked to dramatically increased lung cancer risk

Ris-Rez reduced risk of death by 54% vs. topotecan in patients with relapsed SCLC, phase III trial in China finds

Rybrevant + chemo delivers longest reported median OS in EGFR exon 20 insertion mutation-positive lung cancer

AI imaging endpoint predicts OS benefit in phase III lung cancer trial: data presented at IASLC WCLC 2026

9/11, mRNA, musical chairs—and an assassination attempt

25 years after 9/11, a smoking cessation program may have curbed lung cancer risk for first responders at Ground Zero“We seem to have a risk of exposure that needed that extra boost of the cigarette to cause the cancer.”

Never miss an issue!

Login

25 years after 9/11, a smoking cessation program may have curbed lung cancer risk for first responders at Ground Zero
“We seem to have a risk of exposure that needed that extra boost of the cigarette to cause the cancer.”